絕對生體可用率(%) :20-35%
開始作用(分鐘) : 30分
作用時間(小時) : 8-10
蛋白質結合率(%) : 83-92
半衰期(小時) : 3-7
Other antihypertensive agents
Additive hypotension.
Beta-blockers
May result in increased hypotension and adverse effects because of additive depressant effects on myocardial contractility or AV conduction.
Buspirone
Pharmacologic and adverse effects may be increased by verapamil.
Calcium salts
Clinical effects and toxicities of verapamil may be reversed.
Carbamazepine
Increased carbamazepine serum levels.
Cyclosporine
Increased cyclosporine levels may result.
Dofetilide
Risk of life-threatening ventricular arrhythmias, including torsades de pointes, may be increased. Coadministration with verapamil is contraindicated.
Digitalis glycosides
Increased serum digoxin or digitoxin levels may occur.
Disopyramide
Do not use 48 h before or 24 h after verapamil.
Flecainide
May prolong AV conduction.
Nondepolarizing muscle relaxants
Enhanced muscle relaxant effects and prolonged respiratory depression may occur.
Prazosin
Increased prazosin serum levels may result.
Quinidine
Hypotension, bradycardia, ventricular tachycardia, AV block, and pulmonary edema may occur.
Rifampin
Loss of effectiveness of oral verapamil may occur.
Simvastatin
Plasma levels may be elevated by verapamil, increasing the risk of toxicity (eg, rhabdomyolysis).
2.患有複雜之心肌梗塞及心臟性休克者須慎重給藥及嚴加監督



